Communiqués Pentixapharm Holding AG OTC Markets

Actions

PTPDF

DE000A40AEG0

Produits pharmaceutiques

Marché Fermé - OTC Markets Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^USD	-.--%		-.--%	-

22/07	Pentixapharm lève 16,8 millions d'euros via une augmentation de capital avec maintien du droit préférentiel de souscription	MT
22/07	Eckert & Ziegler : la Bafin examine le bilan 2024 suite à la scission de Pentixapharm	DP

Communiqués

27/07	Pentixapharm Completes Capital Increase – New Shares Placed in Full	EQ
27/07	Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today	EQ
23/07	Pentixapharm Holding AG - Ad-hoc, Rights offering successfully completed, Remaining shares can be subscribed for via private placement	AQ
22/07	Pentixapharm Holding AG: Rights offering successfully completed, remaining shares available for subscription through private placement	EQ
09/07	Pentixapharm Holding AG: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, Granting of 8.922.464 Subscription rights	EQ
09/07	Pentixapharm Receives FDA Fast Track Designation for Phase 3 Diagnostic Candidate [⁶⁸Ga]Ga-PentixaFor in Primary Aldosteronism	EQ
09/07	Pentixapharm Holding AG: Pentixapharm Receives FDA Fast Track Designation for [⁶⁸Ga]Ga-PentixaFor for the Subtyping of Primary Aldosteronism	EQ
03/07	Pentixapharm : English (SD Anh IX Document313414721)	PU
01/07	Pentixapharm Launches Rights Issue to Fund PANDA Phase 3 and U.S. Expansion	EQ
01/07	Pentixapharm Holding AG: Resolves on Rights Issue with an Offering Volume of up to Appr. EUR 20.4 Million; Major Shareholder Eckert Wagniskapital Commits to Fully Exercise Its Subscription Rights	EQ
09/06	[68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market	EQ
09/06	Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program	EQ
11/05	Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic	EQ
10/05	Pentixapharm : Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic	PU
07/05	Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum	EQ
06/05	Pentixapharm : Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum	PU
06/05	Pentixapharm : Financial document (Pentixapharm Q1 2026 e)	PU
29/04	Pentixapharm : Annual General Meeting (Pentixapharm GB 2025 e wbt2)	PU
02/04	Pentixapharm : Financial document (Presentation Earnings Call March 2026 PTX)	PU
31/03	Pentixapharm Holding AG Appoints Erik Merten to the Executive Board	EQ
30/03	Pentixapharm : Appoints Erik Merten to the Executive Board	PU
19/03	Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026	EQ
25/02	Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program	EQ
25/02	Pentixapharm : Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program	PU
05/02	Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism	EQ